Search for Clinical Trial Results
Nasopharyngeal Diseases - 25 Studies Found
Status | Study |
Withdrawn |
Study Name: S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx Condition: Head and Neck Cancer Date: 1999-11-01 Interventions:
|
Not yet recruiting |
Study Name: A Study to Evaluate the Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC Subjects Condition: Nasopharyngeal Carcinoma Date: 2017-04-13 Interventions:
|
Not yet recruiting |
Study Name: Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma Condition: Nasopharyngeal Neoplasms Date: 2017-03-16 Interventions:
|
Not yet recruiting |
Study Name: Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue Condition: Nasopharyngeal Carcinoma Date: 2017-01-19 |
Recruiting |
Study Name: High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer Condition: Metastatic Nasopharyngeal Cancer Date: 2016-12-30 Interventions: Biological: High-activity natural killer Each treatment: 8~10 billion cells in all, transfuion in 3 time |
Not yet recruiting |
Study Name: A Study of Nasopharyngeal Carcinoma From Guangdong Condition: Nasopharyngeal Cancer Date: 2016-12-18 |
Recruiting |
Study Name: Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer Condition: Esophageal Neoplasms [C06.405.117.430] Date: 2016-08-16 Interventions:
|
Recruiting |
Study Name: A Trial of Endostar in Patients With Carcinoma of the Head and Neck Condition: Nasopharyngeal Neoplasms Date: 2016-08-12 Interventions: Drug: Endostar The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receiv |
Recruiting |
Study Name: Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer Condition: Nasopharyngeal Cancer Date: 2016-08-18 Interventions: Drug: Avelumab Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until |
Active, not recruiting |
Study Name: A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) Condition: Cancer Date: 2016-04-22 Interventions: Drug: ARGX-110 |